CRS is a common condition that affects the quality of life of millions of patients worldwide and has a significant impact on health-care resources. Thus, the development of novel biofilm-targeting and antibiotic-sparing therapies is highly desirable and urgently required.
This in vitro study evaluated the antimicrobial activity of a novel synthetic honey-equivalent product designed to have the same reactive oxygen release profile as the engineered honey SurgihoneyRO™.
Treatment efficacy was investigated by assessing planktonic growth, biofilm viability, thickness, and biomass using 12 CRS-related S. aureus mucosal bacterial strains.
Treatment of established S. aureus biofilms reduced biofilm viability with 24-hour treatment resulting in a 2-log reduction in viability of biofilms formed by methicillin-resistant strains and a 1-log reduction in biofilms formed by methicillin-sensitive pieces.
The study concluded that the synthetic honey-equivalent product provides marked antimicrobial activity against S. aureus biofilms, with the potential for development in the clinical setting as adjunctive biofilm-targeted therapy in CRS. The aim of such a product would be to reduce the need for antibiotics, steroids, and invasive surgical procedures in CRS patients and improve clinical outcomes following endoscopic sinus surgery.